Sagility Reports Strong Q2 FY27 Earnings

Revenue from operations reached Rs 2,032.10 crore, while Profit After Tax rose to Rs 284.21 crore.

Reader Takeaway: Sagility shows robust revenue growth and active inorganic expansion, though investors should watch integration risks for new US acquisitions.

What just happened

Sagility Ltd announced its financial results for the quarter ending September 30, 2026. The company posted a 13.3% increase in Profit After Tax to Rs 284.21 crore, compared to Rs 250.83 crore in the year-ago period. Revenue from operations surged by 22.5% to Rs 2,032.10 crore. Additionally, the Board declared an interim dividend of Rs 0.15 per share, with a record date set for October 30, 2026.

Why this matters

The steady financial performance, supported by the highest adjusted EBITDA margin in six quarters, highlights the firm's operational resilience. The planned acquisition of Chirok Health for US$32.35 million reflects a clear strategy to deepen its footprint in the US healthcare market, specifically in clinical documentation and revenue cycle management (RCM).

The backstory

Sagility has been aggressively building its service capabilities through M&A. This follows the successful integration of CareSeed LLC, acquired earlier in June 2026. These moves aim to solidify the company's position within the US payer vertical ahead of the seasonally critical Annual Enrolment Period (AEP).

Risks to watch

Investors should monitor the closing conditions of the Chirok Health deal, as the acquisition is not yet finalized. Furthermore, the management is tracking potential future impacts from the implementation of new Indian labour codes, which remain a point of regulatory monitoring.

What to track next

The market will look for the successful closure of the Chirok acquisition and execution efficiency as the company navigates the upcoming seasonally stronger second half of the fiscal year.